The initial three thyroid assays are canine and feline tT4 (thyroxine), canine free T4, and canine and feline TSH (thyroid stimulating hormone). The Proforma financial statements serve as a basis for the opening entries of both the Assuming Bank and the Receiver. BVSc, MMedVet(Med), PhD, DSAM, Dipl, ECVIM. Zomedica is expected to complete validation studies for TRUFORMA during the fourth quarter of 2019 with a planned commercial launch before the close of first quarter of 2020. As previously announced, TRUFORMA can be installed entirely remotely, which should help limit the impact of the COVID-19 pandemic on instrument installations. The company describes Truforma as a biosensor platform intended for helping veterinarians in diagnosing complex conditions in cats and dogs. Wall Street's IDEXX consensus EPS forecast is $7.5 per share, compared to a current share price of $503, translating to a 67x forward P/E ratio. The companion animal business at Zoetis bought in roughly $3.65 billion in 2020 representing over 50% of the companys overall revenue. This is another case of hype causing a dramatic spike in value. LouisNavellierhad an unconventional start, as a grad student who accidentally built a market-beating stock system withreturns rivaling even Warren Buffett. This was about a 17% improvement in how much money it lost the prior year. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. Investor Relations Contact: PCG Advisory GroupKirin Smith, COOksmith@pcgadvisory.com+1 646.863.6519. Please visit our. Certain cut-off values in the prediction of outcome in puppies with parvoviral diarrhea is discussed. But it wont be a ride in the park for the company. PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. Zomedica, (NYSE American:ZOM), a veterinary diagnostic company, has completed the final verification of three additional assays for use with its TRUFORMA point-of-care diagnostic platform. The combined dynamic range of the canine and feline TRUFORMA tT4 assay is 0.45-30.0 g/dL compared to the Siemens IMMULITE tT4 assay dynamic range of 0.5-15 g/dL. But does the prospect of finally generating revenue justify a 2,500% surge in ZOM stock price in four months? TRUFORMA is the company's innovative diagnostic tool that aims to replace old-fashioned methods of diagnosis that require patient samples to be sent to an outside lab for testing before therapeutic or prescription treatments can be offered. And a successful launch may do just that. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy. But if you simply cant wait, it wasnt so long ago that ZOM stock was trading for less than $2. 3 Stocks That Are Poised to Plunge. Zoetis stock price is near $160. Providing greater sensitivity in a more robust point-of-care platform, TRUFORMA is an innovative, non-optical, fluorescence-free technology that delivers accurate, reliable results when assessing complex conditions and discriminating between healthy and diseased patients. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. His office saves roughly $25 for each test ($70-$45=$25). Delivery Schedule means the schedule for the delivery of Services as set forth in attached Annex 3.. Proforma means producing a balance sheet that reflects a reasonably accurate financial statement of the Failed bank through the date of closing. When youre investing in penny stocks, the axiom that pigs get fat, hogs get slaughtered is apt advice. In his latest feat, Louis discovered the Master Key to profiting fromthe biggest tech revolution of this (or any) generation. Still, you shouldnt arbitrarily have a high expectation that veterinarians would adopt the device quickly. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. TRUFORMA canine and feline assays were evaluated and compared with those of the predicate industry gold standard. Zomedica believes that the TRUFORMA platform represents the first use of BAW technology in disorder and disease-state diagnostics. We dedicate ourselves to serving the needs of the broader veterinary community by offering lab services through Bloodhound laboratories, which will allow our practice partners to also advance their endocrine practice. Assuming successful completion of verification, the goal is to complete . Get daily stock ideas from top-performing Wall Street analysts. According to Zomedica, the time to result for the TRUFORMA TSH assay is less than 20 minutes. Zomedica has five initial assays under development, comprising two panels one each to detect thyroid and adrenal disease. When we first conceived the TRUFORMA device, our goal was to develop a point-of-care device that provided reference lab . Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. To view the original version on ABNewswire visit: Zomedica\s TRUFORMA Expands Suite Of Assays, Revolutionary Platform Readies For Commercialization. Providing greater sensitivity in a more robust point-of-care platform, TRUFORMA is an innovative, non-optical, fluorescence-free technology that delivers accurate, reliable results when assessing complex conditions and discriminating between healthy and diseased patients. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts; uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of our obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Zomedica Corp. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. The pandemic-fueled pet boom is only going to raise that. It allows veterinarians to conduct tests onsite for cats and dogs. We also use third-party cookies that help us analyze and understand how you use this website. I will be able to go above and beyond the current standard of care to provide cutting-edge and novel testing to pet owners and veterinarians in seven surrounding counties across two states. Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Should you invest $1,000 in Zomedica right now? For more information, visit www.ZOMEDICA.com. It will address the effect of critical illness on the hypothalamic-pituitary-adrenal and -thyroidal axes and the use of these hormones in predicting the trajectories of individual patients. PCG may be compensated by respective clients for publicizing information relating to its clients securities. In January, Carole Baskin of Tiger King fame was paid $299 by a fan to mention Zomedia on Cameo. Chris Markoch is a freelance financial copywriter with over five years of experience covering various aspects of the financial markets. Thus, the TRUFORMA canine TSH assay showed a high correlation (R = 0.99) to the Siemens IMMULITE Canine TSH assay. Contact Chris Markoch via email at CTMarkoch@msn.com. And if the company has to wait for some revenue, its best to have some cash on hand. Any internet-connected device can access MyZomedica to view interactive charts, diagnostic tools, and export/print results. The optimism about Truforma based on the growth forecasts for pet diagnostics then seems excessive. This means that the standard extended process of diagnosing these ailments adds to the overall cost of treating cats and dogs. Americans were already spending a fortune on pet health care ($29.3 billion in the vet office in 2019). The information contained on this may be Paid Advertising for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the Securities Act). Is Ollies Bargain Outlets A Value Or A Trap? Uniquely, the TRUFORMA platform uses Bulk Acoustic Wave (BAW) technology, developed by Qorvo, to provide a non-optical and fluorescence-free detection system for use at the point-of-care. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock, 7 Dividend Stocks to Buy That Are Backed by Strong Cash Flows. This is a momentous day for Zomedica, our shareholders, the veterinarians we serve, and the companion animals in their care. The company will release Truforma along with three assays in a limited geographic area as of March 30. Zomedica Appoints New Chief Financial Officer, Zomedica Corporation Reports 2022 Results: $18.9 Million Revenue; 72% Gross Margin & $156 Million in Liquidity Revenue up 361% from 2021 through combination of acquisitions and organic growth, Zomedica to Host Fourth Quarter and Fiscal Year 2022 Financial Results Call on March 15, Zomedica Corp. Diagnostics Initiation Report, Zomedica Reports Preliminary Results for the Fourth Quarter and Full Year 2022, Zomedica to Participate in the Lytham Partners Investor Select Conference, Zomedica to Take Control of New Assay Development and Manufacturing of TRUFORMA Product Line through Long-Term Licensing Agreement with Qorvo Biotechnologies, Zomedica Expands Relationship with Structured Medical Products and Begins Commercializing VetGuardian Wireless Monitors, Zomedica to Present at Sidoti Virtual Investor Conference January 18-19, Zomedica CEO Interview with Wall Street Analyzer Updates Company Progress and Plans. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Despite the drama over the past three weeks, ZOM shares are still up more than 2,500% compared to the value in late October. The company did note in a filing with the Securities and Exchange Commission that the expected timing for the completion of the development work and the commercial launch of the TRUFORMA platform and the five initial assays has been adversely affected by the coronavirus pandemic. The bottom line on Zomedica like so many under-the-radar companies of late is that it caught the attention of the Reddit/Robinhood investing crowd. Individual Registration (beginning October 18) - $130. A highly respected board-certified veterinary internist and neurologist, Dr. Bergs dedication to advancing the field of veterinary medicine has garnered national and international recognition. A feline-optimized TSH assay is not commercially available. It is a credit to all of our employees and their laser focus on advancing TRUFORMA over the last many months that we are able to move into this final phase as we approach the commercial availability of our first product. Without any revenue coming through the door, the best thing that investors can hope for is a less bad earnings report. Fill out the form below and one of our staff will be in touch. Real Madrid are the defending champions, having won their 35th title the previous season.. With the 2022 FIFA World Cup having commenced on 20 November, there was a mid . Enter Truforma, a point-of-care test that veterinarians can use to run such tests in their office. Zomedica Corp. ANN ARBOR, Mich., March 16, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp.(NYSE American: ZOM) (Zomedica or the Company), a veterinary health company creating point-of-care diagnostics products for dogs and cats, yesterday recorded the first veterinarian sale of TRUFORMA and officially entered commercialization. That represents a CAGR of 9.8%. Its not a hard one to call, honestly. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Having a point-of-care cortisol test available also was welcomed by Audrey Cook, BVM&S, Dip ACVIM at Texas A&M College of Veterinary Medicine and Biomedical Sciences: Veterinarians rely on serum cortisol measurements to diagnose and manage adrenal diseases in dogs. Zomedica had $76.7 million on its books at the end of last year as opposed to $14.9 the prior year. Verification data comparing the canine and feline TRUFORMA tT4 assay to the Siemens IMMULITE Canine tT4 reference lab assay showed high correlation (R=0.94). It is mandatory to procure user consent prior to running these cookies on your website. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding the public offering. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Dr. Berg commented that, As a veterinary internist and business owner, I have devoted myself to advancing the practice of veterinary internal medicine and delivering care with a difference doing more, providing more, and caring more. Investor Relations Contact: PCG Advisory Kirin Smith, Presidentksmith@pcgadvisory.com+1 646.823.8656, https://www.linkedin.com/company/zomedica. See what's happening in the market right now with MarketBeat's real-time news feed. You also have the option to opt-out of these cookies. January 18-20, 2022. With the instrument and three of five of the initial assays available for sale, the decision was made to initiate the commercial launch of TRUFORMA ahead of the previously disclosed March 30th schedule. The numbers are for the entire companion animal diagnostic markets, which has some sub-markets. 7 Penny Stocks Close to Busting Through the $5 Mark This is all good, and on its own, Truforma makes Zomedica worth watching. The immediate future of Zomedica hinges heavily on a single about-to-launch product Truforma. These cookies do not store any personal information. The huge gains (and volatility) in ZOM stock are more about Reddit and celebrity endorsements. Having an accurate and reliable, patient-side, cortisol assay will allow veterinarians to manage canine adrenal diseases more effectively and efficiently, and could save lives." But what does Truforma really offer? Dr. Cook has published numerous articles and book chapters on various aspects of small-animal medicine and regularly speaks at national veterinary meetings. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. This webinar will introduce attendees to the use of biomarkers in critical illness; more specifically the use of the endocrine parameters; cortisol and thyroxine in canine critical illness. 2023 InvestorPlace Media, LLC. Investor Relations Contact: PCG Advisory Kirin Smith, Presidentksmith@pcgadvisory.com+1 646.823.8656, Plus500. The big news for Zomedica and any investors who have interest in this company as a long-term holding is Truforma. We also use third-party cookies that help us analyze and understand how you use this website. Due date calculations for Project Center items do not take into account the time an item was created, but are based on full days. Zomedica (ZOM) hasadded ~8.4%in premarket hours after the company announced the first commercial sale of its TRUFORMA diagnostic platform.With the instrument and three of five of. Copyright 5 Hypergrowth Stocks With 10X Potential in 2023, Louis Navellier and the InvestorPlace Research Staff, shoebox-sized point-of-care diagnostic tool for veterinary offices, currently the most common insurance claim for dog owners, 7 Penny Stocks Close to Busting Through the $5 Mark, 7 Sorry Pharma Stocks to Sell in April Before Its Too Late, 5 Penny Stocks With Explosive 5X Potential, Another Rare Bullish Indicator Flashed Last Week. That kicked off a 230% ZOM stock rally. These verification studies evaluate two adrenal assays: canine cortisol and canine eACTH (endogenous adrenocorticotropic hormone). Its not a pretty picture if youre trying to get a handle on where this companys shares are going to go next. The goal then is to add two assays and expand the geographical reach later in the year.. Yet, at $2.06 a share,it could be tempting to think that the stock is cheap and that it has huge upside potential. Importantly, the lower limit of quantification for the feline assay enabled statistically significant (P value = 0.002) discrimination between normal and hyperthyroid feline serum samples. These cookies will be stored in your browser only with your consent. Now available for purchase are TSH, total T4, and cortisol assays. Calculating Due Dates. The launch of the TRUFORMA platform is an exciting and disruptive milestone in the veterinary diagnostics testing industry that will raise the standard of point-of-care for companion animals." Youll have to wait and see. I would like to express my deepest gratitude to the many people at Zomedica who dedicated the past two years of their lives to achieving this critical milestone, commented Robert Cohen, Zomedicas Chief Executive Officer. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. The Launch of Truforma Should Send Zomedica to An All-Time High Fri., March 12, 2021 | Chris Markoch Zomedica (NYSEAMERICAN:ZOM) is a pre-revenue company that is about to bring its first product to market. These cookies will be stored in your browser only with your consent. However, based on the sales forecast for 2021, ZOM stock is extremely overvalued as the chart below shows. New tech for diagnosing dogs and cats could be a pet-care game changer, but uptake by vets isn't certain. The ONLY free-T4 (fT4) assay available at point of care, eliminating inaccurate results due to sample heating during shipment to a reference laboratory. Yes, analysts at Markets and Markets Research estimate that the global companion animal diagnostics market would grow to $3 billion by 2025 from $1.8 billion in 2020. Simply put, more use cases increase the revenue opportunities for ZOM stock. TRUFORMA assays achieve reference lab performance levels. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. 1125 N. Charles St, Baltimore, MD 21201. Necessary cookies are absolutely essential for the website to function properly. Before you consider Zomedica, you'll want to hear this. And that means it has a small sliver of this market. A highly respected board-certified veterinary internist and neurologist, Dr. Bergs dedication to advancing the field of veterinary medicine has garnered national and international recognition. Get Out Now. Heck, the stock was even flogged on Cameo by a celebrity.